Key result
Levosimendan reduces pulmonary vascular resistance index ~27% while improving cardiac index in septic ARDS.
Why the study?
Acute respiratory distress syndrome (ARDS) is frequently associated with increased pulmonary vascular resistance and right ventricular systolic load, and it was unknown whether levosimendan improves hemodynamics by unloading the right ventricle.
Does levosimendan improve right ventricular hemodynamics and pulmonary vascular resistance in patients with ARDS and septic shock?
RCT (n=35)
Placebo-controlled
Randomized
No
Does levosimendan improve right ventricular hemodynamics and pulmonary vascular resistance in patients with ARDS and septic shock?
In patients with ARDS and septic shock, a 24-hour infusion of levosimendan improves right ventricular performance and reduces pulmonary vascular resistance.
Answers are grounded in this paper and cite their sources.
May support levosimendan for acute RV unloading in ARDS/septic shock; extends hemodynamic data to this population.
Objective Acute respiratory distress syndrome (ARDS) is frequently associated with increased pulmonary vascular resistance and thus with systolic load of the right ventricle. We hypothesized that levosimendan, a new calcium sensitizer with potential pulmonary vasodilator properties, improves hemodynamics by unloading the right ventricle in patients with ARDS. Design Prospective, randomized, placebo-controlled, pilot study. Setting Twenty-two-bed multidisciplinary intensive care unit of a university hospital. Patients Thirty-five patients with ARDS in association with septic shock. Interventions Patients were randomly allocated to receive a 24-hr infusion of either levosimendan 0.2 microg/kg/min (n = 18) or placebo (n = 17). Data from right heart catheterization, cardiac magnetic resonance, arterial and mixed venous oxygen tensions and saturations, and carbon dioxide tensions were obtained before and 24 hrs after drug infusion. Measurements and main results At a mean arterial pressure between 70 and 80 mm Hg (sustained with norepinephrine infusion), levosimendan increased cardiac index (from 3.8 +/- 1.1 to 4.2 +/- 1.0 L/min/m) and decreased mean pulmonary artery pressure (from 29 +/- 3 to 25 +/- 3 mm Hg) and pulmonary vascular resistance index (from 290 +/- 77 to 213 +/- 50 dynes/s/cm(5)/m(2); each p < .05). Levosimendan also decreased right ventricular end-systolic volume and increased right ventricular ejection fraction (p < .05). In addition, levosimendan increased mixed venous oxygen saturation (from 63 +/- 8 to 70 +/- 8%; p < .01). Conclusions This study provides evidence that levosimendan improves right ventricular performance through pulmonary vasodilator effects in septic patients with ARDS. A large multiple-center trial is needed to investigate whether levosimendan is able to improve the overall prognosis of patients with sepsis and ARDS.
No takes yet. Share an insight, caveat, or question.
Morelli et al. (2006) conducted an RCT in Acute respiratory distress syndrome (ARDS) with septic shock (n=35). Levosimendan vs. Placebo was evaluated on Right ventricular hemodynamics (cardiac index, mean pulmonary artery pressure, and pulmonary vascular resistance index) (p=<0.05). Levosimendan decreased pulmonary vascular resistance index (290 to 213 dynes/s/cm5/m2) and increased cardiac index in septic ARDS.
Synapse has enriched 10 related papers. Consider them for comparative context: